Remoxipride
Template:Short description Template:Drugbox
Remoxipride (Roxiam) is an atypical antipsychotic (although according to some sources it is a typical antipsychotic) which was previously used in Europe for the treatment of schizophrenia and acute mania but was withdrawn due to toxicity concerns (incidence of aplastic anemia in 1/10,000 patients).[1] It was initially launched by AstraZeneca in 1990 and suspension of its use began in 1993.[1] Remoxipride acts as a selective D2 and D3 receptor antagonist and also has high affinity for the sigma receptor, possibly playing a role in its atypical neuroleptic action.[2]
Due to its short half-life twice daily (bid) dosing is required, although a once-daily controlled-release tablet has been developed.[3] There was some interest in its use in the treatment of treatment-resistant schizophrenia.[4][5]
See also
References
<templatestyles src="Reflist/styles.css" />
Script error: No such module "Check for unknown parameters".
External links
Script error: No such module "Navbox".
Template:Dopamine receptor modulators Template:Sigma receptor modulators